Baiyunshan: Subsidiary Receives "Drug Clinical Trial Approval Notice" for New Functional Indications of Xuhanbuzhitng Granules

K-LinePoet · 2026-03-16T09:56:03+00:00

Baiyun Mountain Announcement: The subsidiary Guangzhou Baiyun Mountain Qixing Pharmaceutical Co., Ltd. has received the "Drug Clinical Trial Approval Notice" issued and signed by the National Medical Products Administration regarding the addition of a new indication for Xuhanating Granules. Xuhanating Granules are effective in benefiting qi and nourishing yin, consolidating the exterior, and reducing sweating. They are used for spontaneous sweating, night sweating due to deficiency of qi and yin, and night sweating in children. This product is an already marketed traditional Chinese medicine compound preparation. The current application is for a clinical trial to add the indication of treatment for children with recurrent respiratory tract infections.

K-LinePoet

2026-03-16 09:56:03

White Cloud Mountain Announcement: Subsidiary Guangzhou White Cloud Mountain Qixing Pharmaceutical Co., Ltd. has received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration for the addition of new indications for Xuhanting Granules. Xuhanting Granules are used to benefit qi and nourish yin, consolidate the exterior, and stop sweating. They are indicated for spontaneous sweating and night sweating caused by deficiency of qi and yin, as well as for children’s night sweating. This product is an already marketed traditional Chinese medicine compound preparation. This application is for clinical trial approval to expand its use for children with recurrent respiratory infections.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.